A review of the last decade: pancreatic cancer and type 2 diabetes

Jiaqi Wu; Liang Tang; Feng Zheng; Xun Chen; Lei Li

doi:10.1080/13813455.2023.2252204

A review of the last decade: pancreatic cancer and type 2 diabetes

Arch Physiol Biochem. 2023 Aug 30:1-9. doi: 10.1080/13813455.2023.2252204. Online ahead of print.

Authors

Jiaqi Wu^{1

2}, Liang Tang³, Feng Zheng⁴, Xun Chen^{5

6}, Lei Li⁷

Affiliations

¹ Nanfang Hospital, Southern Medical University, Guangzhou, China.
² School of Nursing, Southern Medical University, Guangzhou, China.
³ Department of General Medicine, Zhuzhou Central Hospital, Zhuzhou, China.
⁴ Department of Anatomy, University of Otago, Dunedin, New Zealand.
⁵ Department of the Trauma center, Zhuzhou Central Hospital, Zhuzhou, China.
⁶ Department of hepatobiliary surgery, Zhuzhou Central Hospital, Zhuzhou, China.
⁷ Department of Pathology, University of Otago, Dunedin, New Zealand.

PMID: 37646618
DOI: 10.1080/13813455.2023.2252204

Abstract

Pancreatic cancer (PC) is a prevalent gastrointestinal tumour known for its high degree of malignancy, resulting in a mere 10% five-year survival rate for most patients. Over the past decade, a growing body of research has shed light on the intricate bidirectional association between PC and Type 2 diabetes (T2DM). The collection of PC- and T2DM-related articles is derived from two comprehensive databases, namely WOS (Web of Science Core Collection) and CNKI (China National Knowledge Infrastructure). This article discusses the last 10 years of research trends in PC and T2DM and explores their potential regulatory relationship as well as related medications.

Keywords: 10 years; Pancreatic cancer; drugs; relationship; type 2 diabetes.

Publication types

Review